#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Current position of GLP-1 receptor agonists in type 2 diabetes mellitus treatment


Authors: Zbynek Schroner
Authors‘ workplace: Lekárska fakulta, Univerzita Pavla Jozefa Šafárika v Košiciach
Published in: Diab Obez 2024; 24(47): 53-61
Category: Reviews

Overview

In last years significant changes happened in recommendations and algorithms of national and international societies for management of treatment of type 2 diabetes mellitus. Therapy with GLP-1 receptors agonists shows various multiorgan benefits. By these guidelines GLP-1 receptor agonists have important place in therapy of type 2 diabetes. Possible reasons of preference of this treatment are: efficacy, decrease of weight, CV protectivity, slow down the progression of nephropathy, protection of function of B-cells, safety (low risk of hypoglycemia, small incidence of serious adverse events), decrease of blood pressure, lipids, biomarkers of CV risk, markers of chronic subclinical inflammation.

Keywords:

therapeutic place – type 2 diabetes mellitus – GLP-1 receptor agonists


Sources

Davies MJ, Aroda VR, Collins BS et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2022; 45(11): 2753–2786. Dostupné z DOI: <http://dx.doi.org/10.2337/dci22–0034>.

Marx N, Federici M, Schut K et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J 2023; 44(39): 4043–4140. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehad192>.

Martinka E, Tkáč I, Mokáň M et al. Odporúčané postupy pre liečbu diabetes mellitus 2. Typu – 2023. Forum Diab 2023; 12(2): 93–133.

Bays HE, Taub PR, Epsstein E et al. Ten things to know about ten cardiovascular disease risk factors. Am J Prev Cardiol 2021; 5: 100149. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ajpc.2021.100149>.

Mosenzon O, Alguwaihes A, Leon LJA et al. CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries. Cardiovasc Diabetol 2021; 20(1):154. Dostupné z DOI: <https://doi.org/10.1186/s12933–021–01344–0>.

Poznyak A, Grechko AV, Poggio P et al. The Diabetes Mellitus-Atherosclerosis Connection: The Role of Lipid and Glucose Metabolism and Chronic Inflammation. Int J Mol Sci 2020; 21(5): 1835. Dostupné z DOI: <http://dx.doi.org/10.3390/ijms21051835>.

Sattar N, Lee MMY, Kristensen SL et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol 2021; 9(10): 653–662. Dostupné z DOI: <http://dx.doi.org/10.1016/S2213–8587(21)00203–5>.

Marsico F, Paolillo S, Gargiuolo P et al. Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials. Euro Heart J 2020; 41(35): 3346–3358. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehaa082>.

Nauck MA, Quast DR, Wefers J et al. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update. Diabetes Obes Metab 2021; 23(Suppl 3): 5–29. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.14496>.

Visseren FLJ, Mach F, Smulders YM et al. [ESC National Cardiac Societies; ESC Scientific Document Group]. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021; 42(34): 3227–3337. Dostupné z DOI: https://doi: <10.1093/eurheartj/ehab484>.

Labels
Diabetology Obesitology

Article was published in

Diabetes and obesity

Issue 47

2024 Issue 47

Most read in this issue
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#